Raymond James analyst John Ransom notes that Humana (HUM) was down on reports that the cut points for 2026 Stars Ratings, set to be officially announced in October, have gotten harder. This potentially pours cold water in hopes that the company could regain a portion of its lost Stars Ratings for 2026, a year ahead of management’s expectations. Given the 50% rally in the stock off the bottom before yesterday, the firm senses that an improvement in Stars Ratings was increasingly being priced into the stock. In Raymond James’ opinion, the stock was getting a little ahead of itself. The recent pullback creates an attractive buying opportunity, with the implied 2028 valuation now sitting at 6.7x EPS, the firm argues. Raymond James has an Outperform rating on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- UnitedHealth Stock (UNH) Leads Health Insurer Rally, Humana (HUM) Drops
- Court approves CenterWell’s winning bid to acquire assets of The Villages Health
- Managed Care 2026 Star plan cut points look ‘challenged,’ says Leerink
- Another ‘hard year’ for Stars cut points, Hyperlift’s Phillip Collins says
- Humana price target raised to $341 from $269 at Bernstein